清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials

医学 放化疗 软组织肉瘤 放射治疗 内科学 危险系数 比例危险模型 肿瘤科 临床试验 肉瘤 外科 软组织 置信区间 病理
作者
Dian Wang,Jonathan Harris,William G Kraybill,Burton Larry Eisenberg,David G. Kirsch,David S. Ettinger,John Michael Kane,Parul Nafees Barry,A.O. Naghavi,Carolyn R Freeman,Yen‐Lin Chen,Ying J. Hitchcock,Meena Bedi,Kilian Elizabeth Salerno,Diane Marie Severin,Karen D. Godette,Nicole Larrier,Walter John Curran,Pedro A. Torres‐Saavedra,David Robert Lucas
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:9 (5): 646-646 被引量:56
标识
DOI:10.1001/jamaoncol.2023.0042
摘要

Importance: Pathologic complete response (pCR) may be associated with prognosis in patients with soft tissue sarcoma (STS). Objective: We sought to determine the prognostic significance of pCR on survival outcomes in STS for patients receiving neoadjuvant chemoradiotherapy (CT-RT) (Radiation Therapy Oncology Group [RTOG] 9514) or preoperative image-guided radiotherapy alone (RT, RTOG 0630) and provide a long-term update of RTOG 0630. Design, Setting, and Participants: RTOG has completed 2 multi-institutional, nonrandomized phase 2 clinical trials for patients with localized STS. One hundred forty-three eligible patients from RTOG 0630 (n = 79) and RTOG 9514 (n = 64) were included in this ancillary analysis of pCR and 79 patients from RTOG 0630 were evaluated for long-term outcomes. Intervention: Patients in trial 9514 received CT interdigitated with RT, whereas those in trial 0630 received preoperative RT alone. Main Outcomes and Measures: Overall and disease-free survival (OS and DFS) rates were estimated by the Kaplan-Meier method. Hazard ratios (HRs) and P values were estimated by multivariable Cox model stratified by study, where possible; otherwise, P values were calculated by stratified log-rank test. Analysis took place between December 14, 2016, to April 13, 2017. Results: Overall there were 42 (53.2%) men; 68 (86.1%) were white; with a mean (SD) age of 59.6 (14.5) years. For RTOG 0630, at median follow-up of 6.0 years, there was 1 new in-field recurrence and 1 new distant failure since the initial report. From both studies, 123 patients were evaluable for pCR: 14 of 51 (27.5%) in trial 9514 and 14 of 72 (19.4%) in trial 0630 had pCR. Five-year OS was 100% for patients with pCR vs 76.5% (95% CI, 62.3%-90.8%) and 56.4% (95% CI, 43.3%-69.5%) for patients with less than pCR in trials 9514 and 0630, respectively. Overall, pCR was associated with improved OS (P = .01) and DFS (HR, 4.91; 95% CI, 1.51-15.93; P = .008) relative to less than pCR. Five-year local failure rate was 0% in patients with pCR vs 11.7% (95% CI, 3.6%-25.1%) and 9.1% (95% CI, 3.3%-18.5%) for patients with less than pCR in 9514 and 0630, respectively. Histologic types other than leiomyosarcoma, liposarcoma, and myxofibrosarcoma were associated with worse OS (HR, 2.24; 95% CI, 1.12-4.45). Conclusions and Relevance: This ancillary analysis of 2 nonrandomized clinical trials found that pCR was associated with improved survival in patients with STS and should be considered as a prognostic factor of clinical outcomes for future studies. Trial Registration: ClinicalTrials.gov Identifiers: RTOG 0630 (NCT00589121); RTOG 9514 (NCT00002791).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
婉莹完成签到 ,获得积分0
11秒前
Lily完成签到 ,获得积分10
11秒前
免疫小白完成签到 ,获得积分10
12秒前
tangz完成签到,获得积分20
12秒前
tangz发布了新的文献求助30
22秒前
22秒前
老实的乐儿完成签到 ,获得积分10
25秒前
天天向上小螃蟹完成签到,获得积分10
26秒前
HCT完成签到,获得积分10
34秒前
633完成签到 ,获得积分10
36秒前
133完成签到 ,获得积分10
48秒前
阿臭der完成签到 ,获得积分10
49秒前
真实的画板完成签到 ,获得积分10
1分钟前
黄天完成签到 ,获得积分10
1分钟前
crazy完成签到 ,获得积分10
1分钟前
Young完成签到 ,获得积分0
1分钟前
savesunshine1022完成签到,获得积分10
1分钟前
桥西小河完成签到 ,获得积分10
1分钟前
xc完成签到 ,获得积分10
1分钟前
flame完成签到 ,获得积分10
2分钟前
1199完成签到 ,获得积分10
2分钟前
标致的丝完成签到 ,获得积分10
2分钟前
2分钟前
lurq发布了新的文献求助10
2分钟前
DR.秋完成签到 ,获得积分10
2分钟前
Beyond095完成签到 ,获得积分10
2分钟前
qingqingdandan完成签到 ,获得积分10
2分钟前
Chroninus完成签到,获得积分10
2分钟前
2分钟前
Mario发布了新的文献求助30
3分钟前
乐正怡完成签到 ,获得积分0
3分钟前
YY完成签到,获得积分10
3分钟前
wwwwwl完成签到 ,获得积分10
3分钟前
qiongqiong完成签到 ,获得积分10
3分钟前
思源的应助被段无施采纳,获得10
3分钟前
Riversource完成签到,获得积分10
3分钟前
3分钟前
段无施发布了新的文献求助10
3分钟前
在水一方的应助被FIGGIEKIO采纳,获得10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195295
求助须知:如何正确求助?哪些是违规求助? 9581000
关于积分的说明 21873180
捐赠科研通 7795394
什么是DOI,文献DOI怎么找? 3437973
关于科研通互助平台的介绍 2561346
邀请新用户注册赠送积分活动 2484722